Graphite producer and graphene and advanced materials developer, Tirupati Graphite (TGR) resumed its heavy post IPO newsflow momentum by revealing it has commissioned Stage 1 of its Tirupati Graphene and Mintech Research Centre. This is focused on graphene manufacturing and applications development, advanced materials development and mineral processing technology development. Commissioning of Stage 1 marks the start of revenue generating activities from TGMRC and enables the Company to advance current and prospective commercialisation engagements.
Immunodiagnostics group, Oncimmune Holdings (ONC) said it has signed an autoantibody profiling contract with Dana-Farber Cancer Institute, a clinical affiliate of Harvard Medical School. Under this agreement, Oncimmune will be utilising its proprietary biomarker discovery engine, SeroTagTM, to identify autoantibodies that can be predictive of patient response or associated with resistance to checkpoint inhibitors and chemotherapy used in Dana-Farber led studies.
Fast moving West African focused gold company Cora Gold (CORA) announced the eighth set of drill results from its drilling campaign at its Sanankoro Gold Project in Southern Mali. The company said it is focussed on targeting resource growth as well as infill drilling to convert existing Inferred resources to Indicated. The results to date have shown good widths and high-grade results in generally shallow oxide ore. Results at Zone B represent a Phase 1 programme targeting the mineralisation along the previously defined 1.75km strike length of the deposit and demonstrate that there is further mineralisation beyond the existing pit boundaries both at depth and along strike in both directions.
Nanotechnology group Remote Monitored Systems (RMS) delivered notice of a GM, an AGM and a H1 trading update, all contained within a RNS which is characteristically masochistic. It also revealed that its journey to find a new CEO has apparently become more of an epic process than the Star Trek III: The Search For Spock. RMS said marketing of the Pro-Larva face mask has improved, with additional support now being provided to distribution partners in the UK, Europe and India. RMS added that while sales have not been significant to date, it has achieved “encouraging conversations” with potential partners around the world and the Board remains confident that sales will grow in the second half of 2021. Special business for shareholders to consider at the AGM will be to change the name of the Company to nanosynth group plc in line with its proposed rebranding strategy, which will hopefully be more successful than the Windscale / Sellafield switch.
Testing group Abingdon Health (ABDX) has signed an exclusive manufacturing agreement with BioSure, which specialises in the provision of rapid in-vitro diagnostic testing solutions. Under the terms of the exclusive agreement, Abingdon will manufacture BioSure's own lateral flow tests in the field of COVID19. The contract manufacturing services will utilise lateral flow manufacturing facilities at Abingdon's York and Doncaster sites.
Pre-clinical antibody discovery specialist with a notoriously wide spread and occasionall stroppy market makers, Fusion Antibodies (FAB), announced that it has achieved its first research milestone payment for the value of £150,000. This been received as a result of a humanised antibody project that the company has provided services to. While the company said it has the potential for further milestone or royalty payments in respect of a number of projects performed for clients, it is unable to make any estimation of the timing or value of any future revenues from these projects as the success rate and timing is entirely dependent on the customer progressing to clinical trials and commercialisation.
The Gold Rush in terms of listing on the stock market appears to be continuing unabated. Quantum Exponential Limited, which is looking for investment opportunities in the quantum technology sector said it is applying for admission to Aquis. Quantum is set to raise up to £5 million at 5p per ordinary share. Quantum Exponential recently completed a pre-IPO fund raising of £2.5m and is up to £2.3m already. It will be admitted to London’s alternative stock exchange during August. Oberon Capital are acting as sole book runner and broker to the company and Novum Securities are the Corporate Adviser.
